Revlimid和类固醇地塞米松联合用药被批准用于多发性脊髓瘤和罕见病骨髓增生异常综合征的治疗。 其2009年的销售额为17亿美元。

Revlimid, which is approved for multiple myeloma patients in combination with the steroid dexamethasone, and for a rare condition called myelodysplastic syndromes, had revenue of $1.7 billion in 2009.

youdao

Revlimid和类固醇地塞米松联合用药被批准用于多发性脊髓瘤和罕见病骨髓增生异常综合征的治疗。 其2009年的销售额为17亿美元。

Revlimid, which is approved for multiple myeloma patients in combination with the steroid dexamethasone, and for a rare condition called myelodysplastic syndromes, had revenue of $1.7 billion in 2009.

youdao